Evidence map›Paper›PMID 41813748›Full record

ArticleScientific reports2026

Gamma-aminobutyric acid transaminase mediates tumor suppression in renal cell carcinoma through the cGAS-STING-interferon-β axis.

Yi Feng, Senming Cao, Tianwei Cai, Yin Lu, Bin Jiang, Zexuan Lv, Jinlu Tang, Fan Gao, Xupeng Zhao, Chunyu Liu and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yi Feng *Department of Urology, The Third Medical Center of PLA General Hospital, Beijing, China.
Senming Cao *Department of Urology, The Third Medical Center of PLA General Hospital, Beijing, China.
Tianwei Cai *Department of Urology, The Third Medical Center of PLA General Hospital, Beijing, China.
Yin LuDepartment of Urology, The Third Medical Center of PLA General Hospital, Beijing, China.
Bin JiangDepartment of Urology, The Third Medical Center of PLA General Hospital, Beijing, China.
Zexuan LvDepartment of Urology, The Third Medical Center of PLA General Hospital, Beijing, China.
Jinlu TangDepartment of Urology, The Third Medical Center of PLA General Hospital, Beijing, China.
Fan GaoDepartment of Urology, The Third Medical Center of PLA General Hospital, Beijing, China.
Xupeng ZhaoDepartment of Urology, The Third Medical Center of PLA General Hospital, Beijing, China.
Chunyu LiuDepartment of Urology, The Third Medical Center of PLA General Hospital, Beijing, China.
Qi WangDepartment of Urology, The Third Medical Center of PLA General Hospital, Beijing, China.
Ji FengDepartment of Urology, The Third Medical Center of PLA General Hospital, Beijing, China.
Zheng WangDepartment of Urology, The Third Medical Center of PLA General Hospital, Beijing, China.
Qing AiDepartment of Urology, The Third Medical Center of PLA General Hospital, Beijing, China.
Qiang ChengDepartment of Urology, The Third Medical Center of PLA General Hospital, Beijing, China. cxqyisheng@126.com.
Wenmei FanDepartment of Urology, The Third Medical Center of PLA General Hospital, Beijing, China. fan_wenmei@163.com.
Hongzhao LiDepartment of Urology, The Third Medical Center of PLA General Hospital, Beijing, China. urolancet@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is resistant to conventional radiotherapy and chemotherapy, creating an urgent need for novel therapeutic strategies. Although GABA transaminase (ABAT) is involved in metabolic reprogramming as reported, its precise function and molecular mechanisms in ccRCC remain unclear. Here, we demonstrate that ABAT overexpression suppresses tumor growth both in vitro and in vivo. Mechanistically, ABAT mediates the cGAS-STING signaling pathway, and interacts with protein arginine methyltransferase 5 (PRMT5), thereby enhances interferon signaling. Besides, ABAT was found to reduce the infiltration of regulatory T cells within the tumor microenvironment. Collectively, these results suggest that ABAT represents a potential therapeutic target in clear cell renal cell carcinoma.

Indexed as

4-Aminobutyrate TransaminaseCarcinoma, Renal CellInterferon-betaKidney NeoplasmsMembrane ProteinsNucleotidyltransferasesAnimalsCell Line, TumorcGAS-STING Signaling PathwayCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseHumansMiceProtein-Arginine N-MethyltransferasesSignal TransductionSTING ProteinTumor Microenvironment4-Aminobutyrate TransaminasecGAS protein, humanCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseInterferon-betaMembrane ProteinsNucleotidyltransferasesProtein-Arginine N-MethyltransferasesSTING1 protein, humanSTING ProteinccRCCcGAS-STINGGamma-aminobutyric acid transaminaseIFN-βPRMT5

Identifiers

PMID41813748
PMCPMC13100146

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.